ADILライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:36):

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders...

Stats
本日の出来高	122 699
平均出来高	6.52M
時価総額	6.77M
EPS	$-1.154 ( 2024-04-04 )
次の収益日	( $-0.510 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.340
ATR14	$0.0150 (0.90%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Gilliland Robertson H.	Buy	12 000	Stock Option (Right to Buy)
2024-03-25	Newman James W. Jr.	Buy	12 000	Stock Option (Right to Buy)
2024-03-25	Truluck Joseph	Buy	25 000	Stock Option (Right to Buy)
2024-03-25	Claiborne Cary J	Buy	60 000	Stock Option (Right to Buy)
2024-03-25	Anderson J. Kermit	Buy	12 000	Stock Option (Right to Buy)

INSIDER POWER
91.12
Last 98 transactions
Buy: 7 510 922 \| Sell: 1 943 977

ボリューム相関

長: -0.20 (neutral)

短: 0.92 (very strong)

Signal:(53.756) Expect same movement, but be aware

Adial Pharmaceuticals Inc 相関

10 最も正の相関
EXFY	0.967
ELEV	0.966
DRVN	0.965
GSIT	0.964
TSVT	0.963
CMBM	0.958
FGEN	0.956
IPGP	0.956
CMCT	0.952
NNOX	0.951

10 最も負の相関
NVAC	-0.958
PRDO	-0.955
MITA	-0.952
GHIXU	-0.943
WFRD	-0.939
BRIVU	-0.938
MSDA	-0.938
CCRC	-0.935
MMYT	-0.932
DSEY	-0.931

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Adial Pharmaceuticals Inc 相関 - 通貨/商品

0.37
( neutral )

-0.15
( neutral )

0.00
( neutral )

0.11
( neutral )

-0.01
( neutral )

Adial Pharmaceuticals Inc 財務諸表

Annual	2023
収益:	$0
総利益:	$-564.00 (0.00 %)
EPS:	$-5.44

FY	2023
収益:	$0
総利益:	$-564.00 (0.00 %)
EPS:	$-5.44

FY	2022
収益:	$0
総利益:	$-60 501.00 (0.00 %)
EPS:	$-317.81

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-1.971

Financial Reports:

No articles found.

Adial Pharmaceuticals Inc

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.